CD274 and neoplasm: Preliminary observations of patients with recurrent cancers have indicated that clinical responses to immune checkpoint blockers are associated with elevated tumor levels of immune inhibitory signals, such as PD-L1, CTLA-4 and with increased numbers of tumor-infiltrating lymphocytes (TILs) [6, 15–17].